Cornea Abnormality, Cornea Disease, Cornea Inflamed, Exposure Keratopathy, Limbal Stem Cell Deficiency (LSCD), Neurotrophic Keratopathy
Conditions
Brief summary
This retrospective-prospective study aims to identify the diagnostic parameters most predictive of BSCVA in patients with OSD. Clinical, structural, and biochemical data will be collected from standard-of-care examinations and patient-reported outcome questionnaires. The goal is to determine the most informative biomarkers for visual prognosis, streamline diagnostic workflows, and support individualized management of OSD.
Detailed description
The study is based on the hypothesis that specific diagnostic parameters, reflecting corneal structure, ocular surface (including corneal nerve) integrity, inflammatory activity and patients' reported outcomes (questionnaires), can reliably predict BSCVA in patients with OSD. Identifying these predictors will enable evidence-based selection of diagnostic tests, streamline clinical workflows, and improve patient care efficiency. This is a monocentric, national, retrospective-prospective, observational cohort study. The design includes two complementary phases: * Retrospective cohort (n = 1,500): existing clinical records will be reviewed to extract standardized diagnostic and visual acuity data. * Prospective cohort (n = 1,000): newly enrolled patients will undergo a standardized diagnostic protocol and follow-up vists at defined time points. No experimental interventions or off-label diagnostic procedures are included; all assessments correspond to standard-of-care examinations. Overall study duration: Approximately 60 months. Retrospective phase: a cohort of 1,500 patients will be selected among those patients who have been visited at the Cornea Clinic of the OSR in the last 20 years (starting from 01 Jan 2005 to 31 dec 2025) and who have a follow up of at least 12 months. Prospective phase: the investigators will enroll a cohort of 1,000 patients who will be rectruited among those visited at the Cornea Clinic of the OSR and who will be followed up for minimum 12 months. Recruitment will be ongoing for 48 months and the last patient will exit the study by month 60. Individual patient duration: up to 12 months (baseline, 6-, and 12- month visits). Interim analyses are planned at multiple time points throughout the study, contingent on data availability and sample size progression. The precise timing of these analyses will be determined based on the pace of data collection and event occurrence, rather than fixed calendar dates. All data will be collected using standardized, validated diagnostic methods: * Corneal topography (maximum keratometry, Kmax) and pachymetry * In vivo confocal microscopy (corneal nerve density and cellular morphology) * Slit-lamp photography (conjunctival hyperemia and corneal opacity grading) * Cochet-Bonnet esthesiometer (corneal sensitivity) * Goldmann applanation tonometry (intraocular pressure) * Tear cytokine quantification (including IL-1β, IL-6, TNF-α, MMP-9, multiplex immunoassay) * Impression cytology (inflammatory cell counts) * Ocular pain/quality of life questionnaire scores (OSDI, OPAS, VAS, VFQ25, SPEED) Retrospective data will be extracted from electronic medical records, while prospective data will be entered into a dedicated electronic case report form (eCRF) using harmonized acquisition protocols.
Interventions
None listed
Sponsors
IRCCS San Raffaele
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* The participant is willing and able to provide written informed consent for study participation (prospective cohort). * Adult participants aged ≥18 years at the time of inclusion. * Clinically confirmed diagnosis of OSD, including but not limited to inflammatory keratopathies, neurotrophic keratopathy, exposure keratopathy, limbal stem cell deficiency, post-surgical or post-traumatic corneal alterations. * Measurable BSCVA obtained through standardized manifest refraction and ETDRS chart testing at baseline. * Available dataset for the diagnostic tests required by the study (e.g., corneal topography, pachymetry, confocal microscopy, corneal sensitivity testing, slit-lamp imaging, tear cytokine analysis, impression cytology). * Willingness and ability to attend follow-up visits and complete all study-related procedures according to the study schedule.
Exclusion criteria
* Change of retinal, optic nerve, or macular pathology that may affect best spectacle-corrected visual acuity independently of the cornea or ocular surface (e.g., age-related macular degeneration, diabetic macular edema, optic neuropathy) in the period of study * History of intraocular or corneal surgery within 3 months prior to baseline evaluation. * Active intraocular inflammation, glaucoma with uncontrolled intraocular pressure, or corneal conditions not compatible with accurate imaging or measurement (e.g., severe scarring, leukoma). * Uncontrolled systemic diseases that may impair vision or corneal health (e.g., advanced diabetes, autoimmune disease in active phase). * Inability or unwillingness to attend follow-up visits or complete study assessments. * Pregnant or breastfeeding women will not be enrolled, as hormonal fluctuations can alter tear film and ocular surface physiology
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Best spectacle-corrected visual acuity (BSCVA) measured in logMAR | Baseline, 6, and 12 months | Best spectacle-corrected visual acuity will be measured using a standardized Early Treatment Diabetic Retinopathy Study chart at 4 meters after manifest refraction and best spectacle correction. Visual acuity will be reported as logarithm of the minimum angle of resolution. Expected range: -0.3 to 2.0 logMAR. Higher logMAR values indicate worse visual acuity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum keratometry (K max) measured by corneal tomography | Baseline, 6, and 12 months | Maximum keratometry will be measured by corneal tomography. Unit of Measure is Diopters (D). Higher values indicate greater corneal steepening. |
| Central corneal thickness (CCT) measured by corneal tomography | Baseline, 6, and 12 months | Central corneal thickness will be measured by corneal tomography. Unit of Measure is micrometers (µm). Lower values indicate greater corneal thinning. |
| Corneal nerve density measured by in vivo confocal microscopy | Baseline, 6, and 12 months | Corneal nerve density will be measured using in vivo confocal microscopy. Unit of Measure is fibers/mm². Higher values indicate greater corneal nerve density. |
| Corneal sensitivity measured by Cochet-Bonnet esthesiometer | Baseline, 6, and 12 months | Corneal sensitivity will be measured using the Cochet-Bonnet esthesiometer and reported as filament length. Unit of Measure is millimeter (mm). Higher values indicate better corneal sensitivity. |
| Tear fluid interleukin-1 beta (IL-1β) concentration | Baseline, 6, and 12 months | Interleukin-1 beta concentration will be measured in tear fluid samples by tear film analysis. Unit of Measure is pg/mL. Higher values indicate greater inflammatory activity. |
| Tear fluid interleukin-6 (IL-6) concentration | Baseline, 6, and 12 months | Interleukin-6 concentration will be measured in tear fluid samples by tear film analysis. Unit of Measure is pg/mL. Higher values indicate greater inflammatory activity. |
| Tear fluid tumor necrosis factor-alpha (TNF-α) concentration | Baseline, 6, and 12 months | Tumor necrosis factor-alpha concentration will be measured in tear fluid samples by tear film analysis. Unit of Measure is pg/mL. Higher values indicate greater inflammatory activity. |
| Tear fluid matrix metalloproteinase-9 (MMP-9) concentration | Baseline, 6, and 12 months | Matrix metalloproteinase-9 concentration will be measured in tear fluid samples by tear film analysis. Unit of Measure is ng/mL. Higher values indicate greater inflammatory activity. |
| Inflammatory cell count measured by impression cytology | Baseline, 6, and 12 months | Inflammatory cell count will be measured using impression cytology of the ocular surface. Unit of Measure is cells/mm². Higher values indicate greater ocular surface inflammation. |
| Intraocular pressure (IOP) measured by Goldmann applanation tonometry | Baseline, 6, and 12 months | Intraocular pressure will be measured using Goldmann applanation tonometry. Unit of Measure in mmHg. Higher values indicate higher intraocular pressure. |
| Ocular Surface Disease Index (OSDI) score | Baseline, 6, and 12 months | Ocular surface symptoms and vision-related function will be assessed using the Ocular Surface Disease Index questionnaire. The total score ranges from 0 to 100, with higher scores indicating more severe ocular surface disease symptoms. |
| Ocular Pain Assessment Survey (OPAS) quality-of-life interference score | Baseline, 6, and 12 months | Pain-related interference with quality of life will be assessed using the Ocular Pain Assessment Survey quality-of-life interference score. The score ranges from 0 to 10, where 0 indicates no interference with quality of life and 10 indicates maximum interference with quality of life. Higher scores indicate worse pain-related quality-of-life impairment. |
| Visual Analog Scale (VAS) pain score | Baseline, 6, and 12 months | Ocular pain will be assessed using a Visual Analog Scale. The score ranges from 0 to 10, where 0 indicates no ocular pain and 10 indicates the worst imaginable ocular pain. Higher scores indicate worse ocular pain. |
| National Eye Institute Visual Function Questionnaire-25 (VFQ-25) composite score | Baseline, 6, and 12 months | Vision-related quality of life will be assessed using the National Eye Institute Visual Function Questionnaire-25. The composite score ranges from 0 to 100, where 0 indicates the worst possible vision-related quality of life and 100 indicates the best possible vision-related quality of life. Higher scores indicate better vision-related quality of life. |
| Standard Patient Evaluation of Eye Dryness (SPEED) score | Baseline, 6, and 12 months | Dry eye symptoms will be assessed using the Standard Patient Evaluation of Eye Dryness questionnaire. The total score ranges from 0 to 28, where 0 indicates no dry eye symptoms and 28 indicates the most severe dry eye symptoms. Higher scores indicate worse dry eye symptoms. |
Countries
Italy
Contacts
CONTACTGiulio Ferrari, MD, PhD, Professor
Outcome results
None listed